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Abstract
Dementia with Lewy bodies (DLB) patients frequently experience well formed recurrent complex visual hallucinations
(RCVH). This is associated with reduced blood flow or hypometabolism on imaging of the primary visual cortex. To
understand these associations in DLB we used pathological and biochemical analysis of the primary visual cortex to
identify changes that could underpin RCVH. Alpha-synuclein or neurofibrillary tangle pathology in primary visual cortex
was essentially absent. Neurone density or volume within the primary visual cortex in DLB was also unchanged using
unbiased stereology. Microarray analysis, however, demonstrated changes in neuropeptide gene expression and other
markers, indicating altered GABAergic neuronal function. Calcium binding protein and GAD65/67 immunohistochemistry
showed preserved interneurone populations indicating possible interneurone dysfunction. This was demonstrated by loss
of post synaptic GABA receptor markers including gephyrin, GABARAP, and Kif5A, indicating reduced GABAergic synaptic
activity. Glutamatergic neuronal signalling was also altered with vesicular glutamate transporter protein and PSD-95
expression being reduced. Changes to the primary visual cortex in DLB indicate that reduced GABAergic transmission
may contribute to RCVH in DLB and treatment using targeted GABAergic modulation or similar approaches using
glutamatergic modification may be beneficial.
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Introduction
Dementia with Lewy bodies (DLB) accounts for up to
20 % of all dementia cases at autopsy [1]. Clinically DLB
is associated with at least two of the following three core
clinical features: recurrent complex visual hallucinations
(RCVH), fluctuating cognition and parkinsonism [2] or
one of these and one supportive feature (neuroleptic
sensitivity, abnormal dopaminergic imaging of striatum,
or rapid eye movement sleep behaviour disorder) [3]. It
is the presence of RCVH, however, that has been sug-
gested to be one of the most characteristic features of
the disorder, and is associated with increased patient and
caregiver distress and greater likelihood of nursing home
admission and hospitalisation [2].
The RCVH in DLB are described as being well formed
and involve animals, people, and objects [4] and show
some similarities with the visual hallucinations seen in
Charles-Bonnet syndrome and those following occipital
infarction [5, 6]. Illusions and misperceptions are also
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experienced, and the occurrence of passage and presence
hallucinations are also common, as with Parkinson’s
disease (PD) and Parkinson’s disease with dementia
(PDD) [7–9]. Whilst RCVH are one of the core clinical
symptoms of DLB, their aetiological basis is essentially
unknown. DLB subjects do show hypoperfusion and
glucose hypometabolism in the medial occipital lobe in-
cluding the primary and secondary visual cortices [10–
12], which is associated with the visuoperceptual prob-
lems common to both DLB and PDD and may lead to
misidentification or misinterpretation of objects and im-
ages [13]. Such visuoperceptual problems may indicate
parietal and occipital dysfunction and relate to the
RCVH experienced in DLB. RCVH have been suggested
to be due to cortical atrophy, although most neuroradio-
logical studies do not find significant atrophy of the
medial occipital cortex in DLB [14–17] or in PD or PDD
[14, 15, 18]. However, some studies show cortical thin-
ning in the cuneus, precuneus and pericalcarine regions
in DLB [19]. Whilst there appears to be involvement of
the lateral occipital cortex in DLB [11, 12], the only sig-
nificant pathology reported is spongiform change and
gliosis in the medial occipital white matter [20], although
this has not been observed in all studies [21, 22]. Ocular
pathologies may also contribute to RCVH but these are
common in elderly individuals, in addition to DLB and
PD, where clouding, increased central and peripheral
corneal opacity, and macular degeneration also occur
[23, 24]. Changes in visual perception with decreased
capacity to identify motion in spatial suppression tasks
[25], and decreased motion perception [26, 27], along
with reduced acuity [28] and ability to determine images
in the peripheral fields are seen in older persons [29].
Changes in visual acuity are also common in DLB [13]
and in PD [13, 23], although these are not more frequent
than cognitively normal older individuals and the pres-
ence of retinal changes in PD, whilst suggested, has not
been substantiated in some studies [30]. The interaction
between reduced higher cortical activity and an altered
proximal visual system associated with ageing may
therefore contribute to the RCVH seen in DLB.
The well-formed nature of RCVH in DLB suggests
that the ventral visual stream [31, 32] is affected. The
ventral stream from the primary visual cortex projects
to the temporal lobe, including the amygdala. These
areas contain relatively high numbers of LB and it
has been speculated that this may contribute to
RCVH in DLB [33–35] although no differences
between hallucinating and non-hallucinating cases
have been observed. Nonetheless, high densities of
Lewy bodies in the parahippocampal gyrus have been
suggested to relate to early development of RCVH in
both DLB [22] and also PD [24]. Alpha (α)-synuclein
pathology in the retina in DLB [36] and cholinergic
dysfunction in the medial occipital cortex in DLB [37]
have also been observed indicating that pathological
changes in the eye and biochemical changes in the
primary visual cortex could potentially contribute to
RCVH in DLB [38].
Since the possible changes in DLB that could contrib-
ute to RCVH do not stand alone but are part of the
highly complex visual system, the question arises as to
what are the molecular substrates of RCVH in DLB.
Given the paucity of information on pathology in the
primary visual cortex in DLB, but with the presence of a
marked and specific hypometabolic deficit in this region
in DLB [11, 39], it is possible that biochemical abnor-
malities in the visual cortex contribute to RCVH. We
therefore explored this issue and describe here the ana-
lysis of the changes in the primary visual cortex in DLB
using a combination of pathology and stereology to
identify pathological and neuronal involvement, coupled
with transcriptomic analysis of RNA and complimentary
protein determination to determine the biochemical sys-
tems involved. A comparison group of individuals with
Alzheimer’s disease (AD) was used to determine disease
specific changes.
Materials and methods
Clinical samples
All procedures were approved by the Local Research
Ethics Committee and tissue was obtained from the
Newcastle Brain Tissue Resource (NBTR), a UK Human
Tissue Authority approved Research Tissue Bank. The
DLB and AD cases used in both pathological or bio-
chemical series were from several local prospective clin-
ical studies, with participants having clinical assessments
repeated annually where appropriate until death and
agreeing to donate tissue for research purposes. Clinical
diagnoses of DLB and AD were made according to inter-
national consensus criteria [3] and NINCDS ADRDA
criteria [40], respectively. Healthy control subjects were
obtained from NBTR and all such cases had received
thorough case note review to confirm they did not have
cognitive impairment and had normal everyday function
at time of death. The presence of eye disease was identi-
fied through case note review and in all cases this was
identified by standard eye investigations. All cases had
neuropathological confirmation of either having DLB,
AD, or were neuropathologically normal according to
established criteria [3, 41–44]. Cases of DLB had the
presence of visual hallucinations documented by pa-
tient and informant interview through standard clin-
ical interview according to consensus criteria [3] or
were without any documented RCVH (1 case), whilst
AD cases showed an absence of any prior history of
RCVH. Tissue was obtained at post mortem, and the
delay from death to freezing and fixation was noted.
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Tissue from the left hemisphere was rapidly frozen
at -80 °C using pre-cooled copper blocks as approxi-
mately 1 cm thick slices and stored at -80 °C until
use. The right hemisphere was fixed in 10 % forma-
lin and processed by paraffin wax embedding.
For histopathological investigation, a 1 cm-thick cor-
onal block of fixed tissue of the occipital lobe was cut
into a series of 25 × 40-μm-thick tissue slices from a
pre-defined paraffin-embedded coronal block containing
the relevant portion of the middle of the primary visual
cortex from a subset of patients (See Additional file 1:
Table S1). Three of the 25 sections were sampled at
equally spaced intervals (every eight sections) and
stained with cresyl fast violet. The quality of each section
was checked for consistency and the slides coded
(CMM) to ensure that all analysis was carried out blind
to diagnosis. The layers of the primary visual cortex
were delineated and all measurements were taken from
the cortical strip directly surrounding the calcarine sul-
cus. Additional paraffin sections (6–10 μm) were taken
for pathological investigation and stained for myelin
(Loyez stain), and with haematoxylin and eosin to show
general structure. Immunohistochemical investigations
of pathology used a standard ABC peroxidise method
using anti-α-synuclein (KM1, Leica), anti-amyloid β pep-
tide (4G8, Signet), and anti-phosphorylated tau (AT8,
Thermo) and quantified using a standardised morpho-
metric approach [45, 46] (antibody details given in
Additional file 2: Table S6).
Stereology
Neuronal density and volume was estimated within
layers of the primary visual cortex using stereological
analysis software (Stereologer, Chester, MD, USA) to
apply the optical disector [47] and rotator [48] methods
to obtain the density and volume estimates, respectively,
as in our previous studies [49, 50]. Neurones were iden-
tified using standardised criteria: the presence of a Nissl-
stained cytoplasm, pale nucleus and single identifiable
nucleolus in cells that were not spherical unlike glial
cells. The sections were viewed in oil using a Zeiss
Photomicroscope at x 100 objective and a numerical
aperture of 1.25. The microscope was attached to a JVC
colour video camera TK-C1360B (JVC UK Ltd, London,
UK), a motorised x- and y-axis stage accurate to 1 μm
(Optiscan ES110, Prior Scientific Instruments Ltd, Cam-
bridge, UK) and a Heidenhain z-axis depth gauge accur-
ate to 0.5 μm (Heidenhain GB Ltd, London, UK) to
ensure accurate measurement of disector depth.
Based on our previous investigations a random sam-
pling strategy was used and estimates were conducted
using one disector field per field of view and over 120
counts were made per layer examined in each subject to
ensure precise estimates. Each disector frame measured
50 μm long, 50 μm wide and 15 μm deep, with a guard
area of at least 4 μm taken (average μm) above and
below the 3-D disector box, dependent on section thick-
ness measurement. The mean coefficient of error (CE)
for the overall neuronal and glial estimates were calcu-
lated using the Gundersen-Jensen method [51], as previ-
ously [49, 50] and showed that the mean CE for
neuronal volume and density reached an acceptable level
of precision in all layers in all cases measured (P < 0.15)
[51]. There was no significant difference in demographic,
clinical and histopathological information on the study
sample (summarised in Additional file 1: Table S1).
There were no significant differences between the
groups in age, gender, tissue pH, duration of tissue fix-
ation (d.f. = 25, P > 0.05 for all measures), or post-
mortem interval. Mean (±SD) section thickness across
all layers was comparable (d.f. = 25, p = 0.70) between
control (31.82 [1.00] μm), AD (31.58 [0.79] μm) or DLB
(31.89 [0.37] μm) groups after processing.
RNA isolation
The primary visual cortex was identified in blocks of
snap frozen tissue and approximately 50 mg of grey mat-
ter was dissected at -20 °C from a second series of 13
DLB, 12 control, and 13 AD cases with 12 DLB, 12 Con-
trol and 11 AD cases having RNA of sufficient quality
for use and using identical clinical and pathological cri-
teria to the group used for pathological investigation
(see Additional file 3: Table S2) and placed in 5–10
volumes of pre-cooled RNAlater solution (Ambion,
Warrington, UK) and stored at -80 °C. Tissue was re-
moved from RNAlater and rapidly homogenised in TRI-
Reagent (Ambion) and stored at -80 °C. RNA was
extracted using a spin column method as per the manu-
facturer’s instructions (Ribopure, Ambion) and 1ug of
RNA was DNase-treated (Turbo-DNAase free, Ambion).
The RNA concentration was determined using a Nano-
drop ND 1000 Spectrophotometer (Nanodrop Tech-
nologies) and RNA integrity number (RIN) examined
with an Agilent 2100 Bioanalyzer RNA 6000 Nano Assay
(Agilent Technologies, Stockport UK) according to the
manufacturer’s instructions.
Microarray analysis
Control (n = 12) and DLB (n = 12) total RNA samples
were selected as a subset from the second group of pa-
tient material on the basis of tissue pH (>6.0) and RIN
value (>6.0) (see Additional file 3: Table S2) and were
analysed using Illumina Human-6 v2 BeadChips with ap-
proximately 48,000 transcript probes per chip using a
GLP certified facility (Aros, Brensby, Denmark). Data
was imported into R, log2 transformed using a Variance
Stabilizing Transformation [52] and Robust Spline Nor-
malisation algorithm designed for Beadarray data [53].
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Following removal of failed samples and outliers using
hierarchical clustering which excluded two array sam-
ples, significantly altered transcripts were identified in
the limma package [54] and differentially expressed
genes identified by applying cut-offs of p-Value <0.05
(Benjamini-Hochberg FDR correction [55]), and an ab-
solute fold-change of greater than 2. To identify systems
that may be altered/associated with DLB in the primary
visual cortex we used Gene Ontology (GO) to identify
biological process, molecular function and cellular com-
ponent annotations using the GOstats package to test
gene lists for over-represented terms [56] and also Kyoto
Encyclopaedia of Genes and Genomes (KEGG) biochem-
ical pathways.
q-RT-PCR
Reverse transcription of RNA was performed on 1 μg of
total RNA using oligo(dT)12-18 primer (Invitrogen,
Warrington, UK), SupeRNase Inhibitor (Ambion), and
Superscript III Reverse Transcriptase at 50 °C and sam-
ples stored at -80 °C until use. Semi-quantitative RT-
PCR was performed in triplicate using Taqman® assays
(see Additional file 4: Table S5; Applied Biosystems,
Warrington, UK) using Taqman® Universal PCR Master
Mix (Applied Biosystems). A total of 35 different brain
tissue samples with total RNA of RIN > 6.0 were ana-
lysed by q-RT-PCR with 11 control, 12 DLB, and 12 AD
subjects used. ABI PRISM® Sequence Detection System
software was used to generate 2-ΔΔCT values based on
the comparative CT method with GAPDH mRNA as a
reference [57]. To compare the relative gene expression,
a Mann Whitney test was carried out using 2-ΔΔCT
values with significance level of P < 0.05.
Protein determination
Tissue blocks from DLB (mean pH 6.3 ± 0.3), control
(mean pH 6.3 ± 0.4), and AD cases (mean pH 6.0 ± 0.4)
(see case details, Additional file 3: Table S2) of the oc-
cipital lobe were brought to -20 °C in a freezing cabinet
and the primary visual cortex identified. Primary visual
cortex tissue and a small amount of underlying white
matter were isolated using a pre-cooled scalpel. Extrac-
tion was performed by homogenising 100–150 mg of tis-
sue using a rotor stator type homogeniser in ice cold
lysis buffer containing 0.2 M tetraethyl ammonium bi-
carbonate, pH 7.2 (TEAB; Sigma), 1 mM EDTA, and
protease inhibitor tablets (Complete, Roche, Burgess
Hill, UK) and samples stored at -80 °C. Samples were
thawed, made to 0.02 % sodium dodecyl sulphate and
sonicated on ice in a sonicating water bath for 20 min
before protein quantitation was performed using a BCA
Protein Assay kit (Pierce, Cramlington, UK).
Proteins (5–20 μg of protein per sample) were sepa-
rated using NuPAGE 12 % Bis-Tris gels (Invitrogen) with
1x SDS NuPAGE MOPS Running Buffer containing
NuPAGE Antioxidant (Invitrogen). Proteins in the gel
were transferred to nitrocellulose membranes using an
iBlot device (Invitrogen). Membranes were stained with
Ponceau S solution (Sigma) to ensure equal protein
loading, destained with 1x Tris-Buffered Saline (TBS)
0.2 % Tween 20, and stored in 1x TBS 0.2 % Tween 20
at 4 °C overnight. The membrane was incubated with
5 % dried milk in 1x TBS 0.2 % Tween 20 for 30 min at
room temperature to block non-specific protein binding
sites and incubated overnight with primary antibody (see
Additional file 2: Table S6) diluted in 5 % dried milk in 1x
TBS 0.2 % Tween 20 at 4 °C with agitation. Membranes
were then washed for 10 min intervals 3 times with 1x
TBS 0.2 % Tween 20 and incubated a further 30 min with
the appropriate horseradish peroxidase conjugated sec-
ondary antibody at room temperature. Membranes were
washed for 1 h with four washes of TBS 0.2 % Tween 20
then proteins visualised by Enhanced Chemiluminescence
(GE, Amersham, Bucks, UK) and detected using x-ray film
(Fuji, Fisher Scientific, Loughborough, UK). Protein bands
were subsequently quantified using Image-J (NIH). Target
protein expression was determined by normalising to
GAPDH protein expression.
Validated commercial ELISA assays against BDNF (Pro-
mega Corporation, Madison, WI, USA), somatostatin, and
neuropeptide Y (Cambridge Bioscience, Cambridge, UK)
were used according to the manufacturer’s instructions.
Samples of primary visual cortex tissue homogenates were
thawed on ice and centrifuged at 16,000 x g for 20 min at
4 °C and the supernatant collected and diluted 1:20–1:50
in assay diluent buffer and applied to prepared assay
plates. Samples were read along with standards using a
Biotek Synergy Plate Reader. Protein in supernatant sam-
ples was determined using a BCA Protein Assay kit
(Pierce) and specific peptide levels expressed as ng or pg
peptide/mg protein.
Statistical analysis
Analysis of pathology and stereology data involved ana-
lysis of variance (ANOVA), with pairwise comparison of
differences and Bonferroni correction for multiple com-
parisons. PCR data was analysed using Mann Whitney U
tests since the data were not normally distributed and
protein data were analysed initially using Levine’s f-test
to determine homogeneity of variance and differences
using two-way unpaired t-tests. In all cases, P < 0.05 (un-
corrected) was considered significant based on a priori
data from microarray.
Results
Pathology
Pathological investigation of the primary visual cortex in
relation to RCVH, showed no evidence of α-synuclein
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deposition as Lewy bodies or Lewy neurites within pri-
mary visual cortex in any DLB case, with some evidence
of α-synuclein deposition in BA18 as Lewy neurites in
DLB cases, and increased deposition as Lewy neurites
and occasional Lewy bodies in the lateral occipital cortex
(see Fig. 1). The mean intensity of α-synuclein staining in
three occipital regions was recorded for the primary visual,
secondary visual and lateral occipital cortices. No difference
was seen in staining intensity between DLB, AD and con-
trol cases for overall α-synuclein staining intensity. There
was no statistically significant difference between the three
areas in DLB compared to AD (ANOVA: F = (2,147) =
1.328, p = 0.268). A difference in the intensity of staining
was seen between the primary visual, secondary visual and
lateral occipital cortices within the DLB group (ANOVA:
F[2,42] = 7.444, p = .002), with significantly more staining in
secondary visual (114.49 ± 2.84, p = 0.038) and lateral oc-
cipital (119.10 ± 3.05, p = 0.001) cortices, compared to pri-
mary visual cortex (104.99 ± 1.86). A similar significant
difference between the areas was also seen in the AD
Fig. 1 Neurodegenerative Disease Pathology in the Occipital Lobe in Dementia with Lewy Bodies. Representative staining for α-synuclein, Aβ (4G8),
and hyperphosphorylated tau (AT8) in primary visual (BA17), secondary visual (BA18), and lateral occipital cortices (BA37) in DLB cases. An absence of
α-synuclein pathology was seen in BA17, although increasing levels of α-synuclein could be seen in BA18 and in BA37. Similarly, an absence of AT8
(hyperphosphorylated tau) staining was seen in BA17 but increasing levels were seen in BA18 and BA37. Aβ (4G8) pathology was present in all cortical
regions examined. Photomicrographs were taken at x2.5 magnification (upper rows) or at x40 magnification (lower rows) with scale bars at 1000 μm
(upper rows) or 50 μm (lower rows)
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group (ANOVA: F = (2,147) = 32.275, P < 0.001), with
this being significant between the secondary visual
and lateral occipital cortices in AD (p = 0.440). Transcripts
for α-synuclein mRNA were not significantly altered in
DLB compared to controls, and similarly protein analysis
of α-synuclein monomer (18 kDa) showed no significant
change in expression in DLB, and comparable levels of
expression were observed between control and AD sub-
jects (see Additional file 5: Table S3), consistent with pre-
vious studies [58].
Assessment of amyloid-β and tau pathology demon-
strated that the primary visual cortex in AD showed a
high level of amyloid-β pathology in the form of senile
plaque and diffuse amyloid-β deposition, which was sig-
nificantly higher than in controls and also higher than in
DLB (P < 0.005 vs control; P < 0.05 vs DLB, see Add-
itional file 6: Figure S1). Amyloid-β pathology was found
in the occipital cortex in DLB, but was not higher than
in cognitively normal controls. No changes in APP
mRNA expression were seen in the primary visual cortex
using q-RT-PCR in either DLB or AD compared to con-
trols (see Additional file 5: Table S3). Tau pathology, as
assessed by AT8 immunostaining, was present through-
out the occipital lobe in AD cases as neurofibrillary tan-
gles and neuropil threads and was significantly higher
in the primary visual cortex but was minimal or absent
from control and DLB cases (P < 0.05 vs control; P <
0.05 vs DLB, see Additional file 6: Figure S1). No
changes in MAPT (tau) mRNA expression were seen in
the primary visual cortex using q-RT-PCR in DLB, or
AD cases compared to controls (see Additional file 5:
Table S3).
Stereology
Since neurodegenerative pathology in the primary visual
cortex in DLB was not significantly different from that
in normal elderly control individuals, neuronal densities
were determined in the primary visual cortex. There
were no significant differences in neuronal density in
any layer of the primary visual cortex between control
and DLB or AD groups after multiple comparison ana-
lysis (Fig. 2a). However, there was a significant reduction
in neuronal volume in layer 4a in the AD group (p =
0.042; see Fig. 2b) in comparison to the control group.
Furthermore, a significant reduction in neuronal volume
in the AD (p = 0.043) versus control group was found
across all layers when combined. No significant changes
were found in neuronal volume in the DLB group
against control or AD groups in any layer of the primary
visual cortex. Similarly, since hypoperfusion and hypo-
metabolism is a feature of DLB occipital cortex [11], we
determined the presence of capillary density in primary
visual cortex in DLB using Glut-1 staining. No alter-
ations in capillary density were observed in either DLB
or AD brain compared to age matched controls (not
shown) suggesting hypoperfusion and hypometabolism
is not associated with altered capillary density.
Microarray
Owing to the lack of significant α-synuclein pathology
or of major amyloid-β or Tau deposition in DLB and any
significant cell loss in the primary visual cortex in DLB,
whole genome microarrays were used to determine the
changes in gene expression associated with hypoperfu-
sion and hypometabolism. Seventy three genes were seen
to be significantly altered in the primary visual cortex
using the described cut-offs (see Fig. 3 and Table 1). Sev-
eral systems were identified as altered in the primary vis-
ual cortex and linked with DLB most notably in cellular
signalling, synaptic transmission, and vesicle transport
(see Additional file 7: Table S7). However, GO-term ana-
lysis specifically identified GABAergic changes as being
prominent (see Additional file 7: Table S7). For example,
the mRNAs encoding neuropeptide precursor proteins
such as proenkephalin (PENK), tachykinin (TAC1) and
prodynorphin (PDYN) transcripts (see Table 1) were al-
tered. These neuropeptides are primarily expressed by
specific interneurone populations which are also GABAer-
gic. This suggests there may be GABAergic dysfunction in
the primary visual cortex in DLB, a hypothesis supported
by the presence of other GABAergic markers in this pa-
tient group, most notably GAD2 (GAD65) and SLC32A1
and therefore we focussed on the GABAergic system.
Using GAD65/67 to stain GABAergic cells, no alteration
in total counts of cells was seen in the cortex of DLB or
AD patients when compared to control in either primary
visual (ANOVA: F[2,23] = 0.389, p = 0.682) or secondary
visual cortices (ANOVA: F[2,23] = 1.184, p = 0.186; see
Additional file 8: Table S4). This was paralleled by an ab-
sence of any change in GAD1 mRNA transcripts in DLB
relative to control, although a slight but significant reduc-
tion GAD1 mRNA was seen in AD compared to control
(p = 0.0337, uncorrected; Table 2), though AD and DLB
groups were comparable. Similarly, there was no alteration
in GAD65 or GAD67 protein determined by western blot-
ting in either DLB or AD compared to control (see Table 2)
suggesting that GABAergic neurones are still present in
normal numbers but dysfunctional.
Protein
To explore the possibility that GABAergic neurones had
either degenerated or were dysfunctional in specific
neuronal subtypes, numbers of calcium binding protein
containing neurones were quantified to determine if cell
loss was selective. We studied the levels of parvalbumin
(PVALB, mRNA; PVALB, protein), a marker of the fast
spiking basket and chandelier neurones that provide
major inhibitory inputs onto soma and axons of
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pyramidal neurones. PVALB mRNA was significantly re-
duced in DLB (p = 0.0035, uncorrected) compared to
control but was also significantly increased in AD (p =
0.0002, uncorrected) (Table 2) compared to control.
These changes in PVALB mRNA were reflected by
changes in PVALB protein with a reduction of approxi-
mately 15 % in DLB (p = 0.033, uncorrected) and an in-
crease in AD of approximately 25 % (p = 0.0005,
uncorrected) when compared to control. Given the ab-
sence of any reduction in overall GABAergic neurones,
parvalbumin, D-28 calbindin and calretinin neuronal
density in the primary visual cortex was investigated
using stereological methods. No significant change in the
density of these neuronal markers in either DLB or AD
were seen (see Fig. 4) suggesting that whilst the neurones
may show altered marker profiles, their density is un-
changed. To further investigate this, altered marker profile
protein levels for other neuropeptides within the primary
visual cortex in DLB were assessed. Neuropeptide Y levels,
when compared to control, were not significantly in-
creased on ELISA analysis in DLB by (p = 0.22, uncor-
rected) and in AD NPY was increased by approximately
20 % compared to control (p = 0.027, uncorrected) (see
Table 2). Somatostatin levels in primary visual cortex were
unchanged in DLB (p = 0.40, uncorrected) or in AD (p =
0.09, uncorrected) compared to control.
Since previous functional studies have suggested either
decreased inhibition or increased excitatory drive in the
primary visual cortex [59] and in light of the findings
implicating GABAergic neurones based on the micro-
array data, we explored the possibility that altered inhib-
ition was present. To determine if the neuropeptide
changes were associated with alterations in other
GABAergic markers, levels of several proteins involved
in GABA neurotransmission were determined. The
GABAergic post-synaptic marker GABARAP involved in
GABA (A) receptor clustering/transport [60] showed
reduced expression of the 17 kDa GABARAP isoform of
approximately 40 % (P < 0.001, uncorrected) when
compared to control and of the 14 kDa GABARAP
isoform of approximately 30 % (P < 0.001, uncorrected)
in DLB; in AD the 17 kDa isoform was reduced to a
lesser extent by about 15 % (P < 0.001, uncorrected) and
the 14 kDa isoform by 20 % (P < 0.001, uncorrected)
when compared to controls (see Table 2). The GABA
motor protein Kif5A showed a trend towards reduction
in DLB compared to control (p = 0.06, uncorrected), but
no change in AD. Gephyrin, a post synaptic GABA-A
associated protein which anchors GABAergic and glyci-
nergic receptors to the post-synaptic cytoskeleton [61]
showed a significant reduction of approximately 25 %
in DLB compared to control (P < 0.001, uncorrected)
and in AD a reduction of about 20 % (P < 0.0001, un-
corrected). Using ionotropic GABA A1 receptor sub-
unit as an additional marker of receptor activity,
showed no change in either DLB or AD when com-
pared to control (see Table 2).
Since alterations of GABAergic activity may lead to al-
tered net excitation, a series of glutamatergic synaptic
markers were assessed (see Table 2). Using an anti-
VGlut1 (SLC17A7) antibody as a marker of cortical in-
put into the primary visual cortex, we demonstrated
bands from 59–61 kDa, reflecting VGlut1 isoforms ran-
ging from 59.3 to 61.3 kDa. DLB cases were not signifi-
cantly different from controls in VGlut1 isoform 1
(61.3 kDa; p = 0.14), and AD cases were unchanged (p =
0.08, uncorrected). DLB cases were also not significantly
different from controls in VGlut1 isoform 2 (59.3 kDa;
p = 0.72) and AD cases were also not changed compared
to controls (p = 0.78). Similarly the metabotropic glu-
tamate receptor mGluR1 was also unaltered in DLB and
we saw no loss of ionotropic AMPA glutamate receptor
(GluR1/GRIA1) mRNA. As a marker of neural activity
we observed a selective reduction in BDNF mRNA in
the primary visual cortex in DLB cases when compared
to control (P < 0.05, uncorrected; Table 2) but were un-
able to detect BDNF protein in any samples using a spe-
cific ELISA. Whilst variable, there was no change of the
postsynaptic excitatory scaffold protein DLG4 (PSD-95)
mRNA in DLB compared to control, and in AD this re-
duction was significant compared to control (P < 0.05,
uncorrected; see Table 2). PSD95 protein determination,
however, showed a marked 50 % decrease in DLB com-
pared to controls (p = 0.0002, uncorrected), whilst AD
cases showed no change in PSD95 (p = 0.96) in primary
visual cortex compared to control. In line with PSD-95
findings, we identified a reduction of 43 % of the growth
cone marker GAP43 (p = 0.0005, uncorrected), whilst
(See figure on previous page.)
Fig. 2 Neuronal density (a) and Neuronal volume (b) within the individual layers and across all layers (overall) of primary visual cortex in dementia
with Lewy bodies (DLB) and Alzheimer’s disease (AD). a Stereological analysis using the optical disector was used in primary visual cortex to
determine neuronal density. No change in neuronal density was seen in DLB or AD. Boxplots show the median and quartile range with whiskers as
the highest and lowest values within 1.5 x the interquartile range. ●, outlier points. b No overall reduction in neuronal volume was observed in DLB
compared to elderly controls. There was a significant overall reduction in neuronal volume in AD compared to control and specifically a significant
reduction in neuronal volume in layer 4a in AD (P < 0.05). Boxplots show the median and quartile range with whiskers as the highest and lowest
values within 1.5 x the interquartile range. ●, outlier points. †, P < 0.05
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AD cases showed no change (p = 0.11) when compared
to control in DLB primary visual cortex. As markers of
synaptic neurotransmission, we determined synaptophy-
sin as a marker for presynaptic vesicular membranes
and SNAP25 levels as a marker of presynaptic vesicles.
Synaptophysin showed a marked and significant 44 %
decrease compared to control in DLB cases (P < 0.00001,
uncorrected) and also a lesser 22 % decrease in AD
cases compared to control (p = 0.01, uncorrected).
DLB cases, however, showed no change in SNAP25
expression compared to controls (p = 0.43), and simi-
larly AD cases also showed no significant change in
SNAP25 expression compared to controls (p = 0.13)
indicating general exocytosis was unaltered.
Discussion
Visual hallucinations have a complex aetiology with the
potential involvement of multiple systems including the
eye, primary visual cortex, and higher order brain re-
gions [5, 6]. This study showed an absence of demon-
strable neuropathological changes in primary visual
cortex with no significant evidence of Lewy body- or
AD- pathology or neuronal change in DLB, and similar
to other studies [21], with the presence of mild path-
ology in adjacent occipital cortical regions. Recent evi-
dence suggests that occipital involvement may be seen
in individuals with PD with concomitant AD pathology,
and also in cases with a clinical presentation of AD with
the presence of Lewy bodies, although the presence of
α-synuclein pathology within the primary visual cortex
was not noted specifically [62]. This may indicate that
the primary visual cortex could indeed be affected by
pathology in DLB, if there are high levels of coexisting
AD pathology, although in the current study such cases
were not included. Whilst some studies show an absence
of laterality in structural MRI in DLB [63, 64], some
studies show lateralised changes [19], and therefore the
current study, since it only determined cell counts and
pathology in one hemisphere, may miss any unilateral
changes. While the stereological approach used investi-
gated all layers of the primay visual cortex, there may be a
potential bias towards estimating pyramidal neurone
Fig. 3 Microarray Analysis of Gene Expression in the Primary Visual Cortex in DLB. Total RNA samples were applied to Illumina whole genome
transcript arrays and following analysis upregulated or downregulated transcripts analysed using hierarchical clustering and significantly altered genes
were used to determine groups of genes associated with altered expression in DLB (Blue) compared to controls (Red) using a heatmap approach. DLB
cases showed clustering with the exception of one DLB case (*) which had no known evidence of RCVH located within the control group
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Table 1 Microarray analysis of Gene Expression in Primary Visual Cortex in DLB
symbol name logFC adj.P.Val
PENK proenkephalin 2.328 0.003
HTR2C 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled 2.029 0.001
SOWAHA sosondowah ankyrin repeat domain family member A 1.588 0.001
MAL2 mal, T-cell differentiation protein 2 (gene/pseudogene) 1.583 0.001
TAC1 tachykinin, precursor 1.537 0.003
FKBP1A FK506 binding protein 1A, 12 kDa 1.527 0.001
PRKCB protein kinase C, beta 1.489 0.003
ENTPD3 ectonucleoside triphosphate diphosphohydrolase 3 1.452 0.022
ELMOD1 ELMO/CED-12 domain containing 1 1.436 0.001
RTN4 reticulon 4 1.409 0.001
ATP2B1 ATPase, Ca++ transporting, plasma membrane 1 1.388 0.003
GPR6 G protein-coupled receptor 6 1.387 0.003
PPP3CA protein phosphatase 3, catalytic subunit, alpha isozyme 1.372 0.002
COCH cochlin 1.355 0.005
CRYM crystallin, mu 1.334 0.035
SLC32A1 solute carrier family 32 (GABA transporter), member 1 1.329 0.010
PRKCB protein kinase C, beta 1.318 0.006
AP1S1 adaptor-related protein complex 1, sigma 1 subunit 1.297 0.001
GUCY1A3 guanylate cyclase 1, soluble, alpha 3 1.285 0.004
FGF13 fibroblast growth factor 13 1.265 0.001
SYT1 synaptotagmin I 1.243 0.009
GABRA5 gamma-aminobutyric acid (GABA) A receptor, alpha 5 1.236 0.020
CT45A1 cancer/testis antigen family 45, member A1 1.230 0.047
LPL lipoprotein lipase 1.226 0.007
MAP7D2 MAP7 domain containing 2 1.199 0.004
PDYN prodynorphin 1.196 0.046
TSPAN13 tetraspanin 13 1.182 0.003
PDP1 pyruvate dehyrogenase phosphatase catalytic subunit 1 1.180 0.003
TUSC3 tumor suppressor candidate 3 1.164 0.001
NELL2 NEL-like 2 (chicken) 1.161 0.010
SSX2IP synovial sarcoma, X breakpoint 2 interacting protein 1.153 0.001
SYN2 synapsin II 1.151 0.009
ITPR1 inositol 1,4,5-trisphosphate receptor, type 1 1.150 0.003
AP1S1 adaptor-related protein complex 1, sigma 1 subunit 1.147 0.001
AP1S1 adaptor-related protein complex 1, sigma 1 subunit 1.139 0.003
GAD2 glutamate decarboxylase 2 (65 kDa) 1.132 0.014
PPP4R4 protein phosphatase 4, regulatory subunit 4 1.125 0.002
ANKRD34B ankyrin repeat domain 34B 1.123 0.003
ATP2B1 ATPase, Ca++ transporting, plasma membrane 1 1.117 0.005
NSF N-ethylmaleimide-sensitive factor 1.112 0.002
BTBD10 BTB (POZ) domain containing 10 1.105 0.001
SCN2B sodium channel, voltage-gated, type II, beta subunit 1.099 0.003
NSF N-ethylmaleimide-sensitive factor 1.087 0.002
RTN1 reticulon 1 1.083 0.005
Khundakar et al. Acta Neuropathologica Communications  (2016) 4:66 Page 10 of 18
changes since pyramidal neurones can be more readily
identified in Nissl stained sections compared to small
interneurones. The lack of any changes in any cortical
layers enriched for pyramidal neurones in DLB would sug-
gest no major alterations in pyramidal neurones due to
oversampling. Additionally, the results from directly deter-
mining interneurone density changes which also appear
unchanged in DLB (Fig. 4) suggest that any possible bias
towards sampling large pyramidal neurones in the current
study is likely to be small. The current results, however,
suggest that occipital hypoperfusion and hypometabolism
seen in conjunction with RCVH is not due to neuro-
degeneration within the primary visual cortex. Similar
findings of reduced perfusion and metabolism includ-
ing within occipital cortex in PD and in relation to
visual hallucinations may indicate that the findings
here in DLB may also relate to PD, although this will
require further investigation [65–67]. In relation to
the findings in AD, however, the presence of major
pathology and also of neuronal atrophy, may indicate
that the primary visual cortex is simply less respon-
sive to stimulation, and consequently RCVH in AD
are not common findings due to neurodegeneration.
Because of the absence of pathology in DLB, we used a
transcriptomic approach to determine the gene expression
changes that may underpin possible changes in the pri-
mary visual cortex. The current findings indicate there is
an alteration in the profile of several genes and changes in
GABA and neuropeptide markers indicate changes in the
interneurone pool. Whilst the microarray findings show
Table 1 Microarray analysis of Gene Expression in Primary Visual Cortex in DLB (Continued)
PARM1 prostate androgen-regulated mucin-like protein 1 1.078 0.010
ANO3 anoctamin 3 1.076 0.029
CRYM crystallin, mu 1.072 0.030
CNR1 cannabinoid receptor 1 (brain) 1.072 0.039
LPPR4 lipid phosphate phosphatase-related protein type 4 1.069 0.001
MAP2K1 mitogen-activated protein kinase kinase 1 1.065 0.001
AKAP11 A kinase (PRKA) anchor protein 11 1.054 0.001
INPP5A inositol polyphosphate-5-phosphatase, 40 kDa 1.043 0.027
PAM peptidylglycine alpha-amidating monooxygenase 1.041 0.006
ERICH3 glutamate-rich 3 1.041 0.003
HPRT1 hypoxanthine phosphoribosyltransferase 1 1.030 0.001
ABHD12B abhydrolase domain containing 12B 1.025 0.002
NBEA neurobeachin 1.024 0.002
HS6ST2 heparan sulfate 6-O-sulfotransferase 2 1.021 0.001
DNAJC12 DnaJ (Hsp40) homolog, subfamily C, member 12 1.011 0.001
DCLK1 doublecortin-like kinase 1 1.010 0.018
DNAJC12 DnaJ (Hsp40) homolog, subfamily C, member 12 1.000 0.002
SLC14A1 solute carrier family 14 (urea transporter), member 1 −1.020 0.033
IL4R interleukin 4 receptor −1.071 0.039
GSTM1 glutathione S-transferase mu 1 −1.090 0.025
SQSTM1 sequestosome 1 −1.098 0.044
VWF von Willebrand factor −1.101 0.039
NPIPB4 nuclear pore complex interacting protein family, member B4 −1.141 0.004
TAGLN transgelin −1.178 0.004
LOC285407 asparagine-linked glycosylation 1 homolog pseudogene −1.184 0.001
TMEM137 TMEM137 −1.244 0.002
HBA2 hemoglobin, alpha 2 −1.382 0.043
TXNIP thioredoxin interacting protein −1.522 0.003
Listing of significantly altered genes (±2.0 fold change, FDR < 0.05) from the whole genome microarray are displayed along with their average fold change.
Neuropeptide/GABAergic interneurone markers are highlighted in bold
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synaptic, and specifically GABAergic, changes, the major
interneurone population is still intact based on the density
of calcium binding protein positive neurones present,
underscoring that dysfunction rather than degeneration
occurs in the primary visual cortex in DLB. We have,
however, not shown the presence of major changes in the
levels of these calcium binding proteins and so it is diffi-
cult to determine if one specific group of interneurons is
affected, although the microarray data appears to indicate
that several groups of interneurons are affected, particu-
larly enkephalinergic and tachykininergic neurones (see
Table 1). Although the transcriptomic and morphological
changes in the primary visual cortex point towards dys-
function, the underlying changes in neurotransmission
that regulate this region require definition and synaptic
changes associated with both inhibitory interneurones and
excitatory neurones are present. Since RCVH are a very
common feature of DLB (this study had access to only
one case of DLB without RCVH; see Fig. 3) our findings
may relate to an intrinsic property of the primary visual
cortex in DLB, since while we used an AD group to look
at degenerative changes, RCVH are not common in AD.
The changes we have identified may therefore be a unique
feature of DLB, rather than simply due to RCVH. The lo-
cation of the individual case of DLB without RCVH in the
control cluster following microarray would though indi-
cate that the microarray findings may be linked to RCVH.
Additional studies with cases of DLB where there is a well
documented absence of hallucinations will be required to
resolve this issue.
The current transcriptomic analysis points to altered
synaptic function and specifically GABA dysfunction in
Table 2 GABAergic Interneurone Markers and Glutamatergic Markers in the Primary Visual Cortex in Dementia with Lewy Bodies
and Alzheimer’s disease
Protein/mRNA Control DLB AD
GAD1 mRNA 1.46 ± 0.62 0.86 ± 0.22 0.62 ± 0.15*
GAD67 protein 0.85 ± 0.21 0.85 ± 0.16 0.72 ± 0.13
GAD65 protein 1.12 ± 0.26 1.16 ± 0.26 0.91 ± 0.15
PVALB mRNA 1.59 ± 0.47 0.87 ± 0.24† 3.51 ± 0.55**
PVALB protein 0.70 ± 0.22 0.61 ± 0.25* 0.87 ± 0.25***
NPY pg/mg 5.71 ± 1.95 6.63 ± 1.62 7.39 ± 1.52*
SST ng/mg 0.42 ± 0.18 0.48 ± 0.15 0.60 ± 0.27†
GABARAP-17 kDa 1.56 ± 0.28 0.91 ± 0.19*** 1.29 ± 0.28**
GABARAP-14 kDa 1.47 ± 0.27 0.99 ± 0.14*** 1.15 ± 0.26**
Gephyrin 1.13 ± 0.27 0.84 ± 0.08** 0.67 ± 0.09**
GABA A α1 0.75 ± 0.30 0.82 ± 0.26 0.83 ± 0.39
Kif5A 0.95 ± 0.58 0.51 ± 0.10† 0.90 ± 0.09
GRIN2A mRNA 1.44 ± 0.79 0.70 ± 0.16 0.89 ± 0.31
GluR1/GRIA1 protein 0.94 ± 0.13 0.89 ± 0.33 NT
vGlut1(SLC17A7) protein 61.3 kDa 1.20 ± 0.24 1.04 ± 0.18 0.91 ± 0.11†
vGlut1(SLC17A7) protein 59.3 kDa 0.90 ± 0.13 0.87 ± 0.1 0.90 ± 0.12
PSD95 (DLG4) mRNA 3.33 ± 1.14 1.80 ± 0.61† 0.83 ± 0.26*
PSD-95 protein 1.25 ± 0.22 0.62 ± 0.19*** 1.24 ± 0.28
GAP43 protein 1.25 ± 0.45 0.71 ± 0.22*** 1.08 ± 0.16
BDNF mRNA 0.70 ± 0.16 0.39 ± 0.14* 0.71 ± 0.48
BDNF protein ND ND ND
Synaptophysin (SYP) mRNA 1.76 ± 0.72 0.89 ± 0.22 2.69 ± 0.80
Synaptophysin protein 0.96 ± 0.25 0.54 ± 0.09*** 0.72 0.16*
SNAP25 mRNA 1.27 ± 0.30 0.88 ± 0.23 0.83 ± 0.25
SNAP25 protein 1.10 ± 0.28 0.99 ± 0.13 1.10 ± 0.17
Relative expression levels (+/- SEM) for GABAergic interneurone marker transcripts and proteins in control, DLB and AD primary visual cortex were determined
using validated Taqman assays by real time PCR and proteins determined using western blotting of the appropriate protein band with relative expression levels
being normalised to GAPDH mRNA or protein. Values represent the 2-ΔΔCT value for mRNA and protein/GAPDH for the specific protein. NPY and SST levels were
determined using specific sandwich ELISA. Uncorrected p values are presented with, *, P < 0.05 relative to control; **, P < 0.01 relative to control; ***, P < 0.005
relative to control; †, P < 0.1, >0.05. BDNF protein was not detected (ND) in any samples using an ELISA method
NT Not tested
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Fig. 4 (See legend on next page.)
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DLB (see Additional file 7: Table S7). The changes in
GABAergic interneurones suggest that there may be par-
allels with the changes seen in the primary visual cortex
following reduced visual input in animals [68, 69]. Here,
reduced input leads typically to functional changes in in-
hibitory interneurones with a reduced expression of par-
valbumin in fast spiking interneurones [70]. There are
also changes in the primary visual cortex following
reduced stimulation with an increased turnover of syn-
aptic boutons of interneurones both acutely and chron-
ically [71, 72]. While much of this work has been
conducted in the mouse, primate work also suggests a
loss of GABAergic interneurone function following de-
creased input and this may occur acutely in man [73].
The hypometabolism seen in DLB in the medial occipital
lobe in DLB may also relate to decreased GABA func-
tion since, studies support the possibility that blood flow
is reduced with reduced GABA activity [74–76], al-
though studies also indicate that increasing GABA levels
causes reduced blood flow in younger subjects [77]. The
reduced expression of GABAergic markers such as
gephyrin and GABARAP may be an indication of the
eye pathology frequently found in DLB patients and in
ageing [13, 23]. DLB patients frequently show visuo-
perceptual impairments and the presence of severe ocu-
lar pathology may reduce input to the primary visual
cortex [13, 78] although the presence of eye disease is
not a universal feature of DLB (Additional file 1: Table
S1 and Additional file 3: Table S2). Conversely, environ-
mental enrichment in mice leads to enhanced BDNF
expression in the primary visual cortex [79], which con-
trasts with the potentially decreased BDNF mRNA ex-
pression seen in DLB cases in the current study (see
Table 2). Visual input regulates the expression of BDNF
mRNA [80] in glutamatergic neurones with reduction of
BDNF leading to altered GABAergic transmission [81].
Changes within the eye [82], an absence of retinal thin-
ning [83] and an absence of pathology within the lateral
geniculate nucleus [84] indicate that not all DLB patients
have eye disease (see Additional file 1: Table S1 and
Additional file 3: Table S2) and this suggests that RCVH
therefore do not require pathology within the eye or
proximal visual system to occur or for hypometabolism
and hypoperfusion to be present in the primary visual
cortex. It is possible therefore that the findings indicate
a stereotyped response of the primary visual cortex in an
attempt to increase excitation by reducing post synaptic
inhibitory synapses and decreasing inhibition, and would
support the suggestion of decreased inhibition as a fac-
tor in RCVH in DLB [85]. Alternatively, the hypoperfu-
sion and hypometabolism seen in the primary visual
cortex in DLB may be due to lesions in other brain
regions. Increased perfusion following cholinesterase in-
hibitor treatment occurs in lateral and posterior occipital
cortex in DLB, and this may indicate that pathology
within the basal forebrain cholinergic system may be in
part responsible for the reduced perfusion observed [86].
Whilst there is a relatively selective reduction in perfu-
sion of the primary visual cortex in DLB compared with
AD, this is on a background of generalised hypometabo-
lism involving temporal, parietal, and occipital regions
when compared to elderly cognitively normal individuals
[11, 87], and therefore other brain regions may poten-
tially influence the perfusion and metabolism within the
primary visual cortex.
This study indicates the presence of altered GABAer-
gic synapses in DLB. Previous investigations of synaptic
markers in the primary visual cortex in DLB have sug-
gested loss of SNAP25 and syntaxin which we did not
observe in the current study. In prior studies this may
be due to the use of indirect ELISA determination with
potential cross reactivity of antibodies, which would not
be seen with our more robust western blotting approach
[88]. Demographic factors, including longer post mor-
tem interval and lower brain pH (indicating poor agonal
state), are known to negatively affect synaptic protein
levels [89] and will have influenced previous investiga-
tions. Our results are more in line with preserved func-
tion that would be seen with preserved SNAP25 levels,
which is essential for neurotransmitter exocytosis [90].
Studies in other brain regions (e.g. frontal cortex) in
DLB have shown relatively preserved synaptic markers
[91, 92], which would correlate with the selective loss of
certain marker proteins, rather than a generalised loss of
synapses per se. The current results suggest connectivity
is selectively altered in the primary visual cortex of DLB,
with a change in specific synaptic marker proteins and
genes, for example PSD95, compared to the atrophy as-
sociated changes seen with AD. PSD95 is specifically as-
sociated with the excitatory post-synaptic membrane
[93]. Whilst the major input to the primary visual cortex
from the lateral geniculate nucleus appears normal [84],
input from adjacent visual cortical areas (secondary vis-
ual cortex, etc.) and through secondary visual pathways
via the pulvinar occur, and so reductions in PSD95 may
represent such defects. Using VGlut1 as a marker of
(See figure on previous page.)
Fig. 4 Analysis of Interneurone Populations in the Primary Visual Cortex in Dementia with Lewy Bodies and Alzheimer’s Disease. Immunohistochemistry
for a) parvalbumin, b) calretinin, and c) calbindin was used to label specific interneurone populations in the primary visual cortex and neuronal density
determined. No significant loss of interneurone populations was observed in either DLB or AD in the primary visual cortex. 0, outlier points
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cortico-cortical connections, we observed no significant
reductions in VGlut1 in DLB but observed reductions in
VGlut1 in AD where there was a general reduction along
with atrophy in excitatory neurones (Fig. 2) due to path-
ology [94]. This would indicate that intrinsic and major
cortical glutamatergic synapses are not lost in DLB but
that changes within glutamatergic neurones may repre-
sent the observed changes in PSD-95. This supports the
concept of reduced visual system input to the primary
visual cortex as being part of the process of generation
of RCVH in DLB as with other primary visual system le-
sions [5] and that “bottom up” changes are important in
RCVH as has been noted for PD [95].
The changes in GABA neurotransmission may have a
clinical correlate within the symptomatology of RCVH
in DLB. Altered GABA neurotransmission may be ob-
served as a change in the excitability of pyramidal neu-
rones where in DLB, the use of transcranial magnetic
stimulation of the occipital cortex (occiput) is correlated
with increased generation of RCVH like phosphenes
[96] possibly as a result of decreased inhibition. Reduced
levels of parvalbumin, such as seen in this study, have
been suggested to cause altered cortical gamma oscilla-
tions whereby the gain and modulation of firing of pyr-
amidal neurones is affected [97, 98]. Desynchronisation
of pyramidal neurones in the primary visual cortex and
net increased excitability due to reduced inhibition may
therefore lead abnormal outflow to higher order visual
areas which appear to show changes in DLB [78] result-
ing in RCVH.
The presence of reduced visual input into the primary
visual cortex in DLB, whilst being part of the aetiology
of RCVH, does suggest that further changes must con-
tribute to RCVH. For example, RCVH do not necessarily
occur in blind individuals, and this suggests that other
pathological or biochemical changes are required in
order to result in RCVH [78]. Considerable attention
has focussed on changes in temporal lobe structures
in DLB and also PD in relation to visual hallucina-
tions [7, 78]. Pathological correlates have indicated
that temporal lobe Lewy bodies correlate with the
presence of RCVH [33] and that, in PD, elevated
Lewy body density in the basolateral nucleus of the amyg-
dala and temporal lobe associate with RCVH [24, 34].
Structurally, however, there is relative preservation of the
temporal lobe in DLB [17], although this may not be the
case in PD with RCVH [99]. This is accompanied in DLB
with decreased connectivity of the temporal lobe [78, 100]
and perfusion deficits, specifically in the ventral occipito-
temporal junction following visual stimulation of DLB pa-
tients with frequent and more severe RCVH [63].
Our results therefore show that, in the absence of
major pathological changes in the primary visual cor-
tex in DLB, there are functional changes associated
with GABAergic neurones. This may reflect a change
to the visual input due to reduced visual acuity as a
consequence of age related changes in the eye. These
changes lead to an inhibitory/excitatory imbalance in
the primary visual cortex and altered perception of
visual stimuli due to changes in association cortex.
One possibility is that by treating major eye disease
where it is present, by opting for a more proactive
approach, RCVH may be reduced [101]. Alternatively,
modulation of GABAergic inhibition using selective
modulators of specific GABA receptors might be feas-
ible to determine if RCVH are reduced in small scale
clinical trials, using appropriate scales for estimating
RCVH frequency and severity [63, 78]. Modulation of
glutamatergic signalling may also be of benefit,
perhaps by acting on group II metabotropic gluta-
matergic receptors, again in small scale experimental
studies using appropriate scoring systems for RCVH
[102]. It may therefore be possible to ameliorate the
recurrent visual hallucinations perceived by DLB pa-
tients using appropriate interventions.
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